NF2-BioSolutions_Final-01-2-300x159.png

About

Neurofibromatosis 2 (NF2) is a rare genetic disorder that is primarily characterized by noncancerous (benign) tumors of the nerves that transmit balance and sound impulses from the inner ears to the brain (bilateral acoustic neuromas/vestibular schwannomas). NF Biosolutions is partnering with CBTN on biobanking and research efforts to discover the underlying causes and identification of potential treatments through molecular analysis.

related

Resources

Project

Asset 20.png

Specimen

Planning

Evaluation of Drug Vulnerability of NF2 Tumor Models

Neurofibromatosis type 2 (NF2) tumors are very rare and understudied tumors. Using high quality specimens provided by the Children’s Brain Tumor Network, researchers will run broad drug interaction experiments in an effort to identify treatments for this rare tumor.

Joe Kissil

Joseph Kissil

Moffitt Cancer Center
Tampa, FL, USA

Project

Asset 9.png

Specimen

Planning

Pre-clinical Studies for NF2 Schwannomas

There is a great need for pharmaceuticals that can treat NF2 tumors. Using specimens made available through the Children’s Brain Tumor Network, researchers look to support clinical trial research through the identification of NF2 drug targets.

christina fv

Christina Fernandez-Valle

University of Central Florida
Orlando, FL, USA

Project

Default project image

Biomarker Identification for Neurofibromatosis Type 2 Background

The identification of biomarkers related to NF2-associated brain tumors such as schwannomas, meningiomas, and ependymomas could lead to advancements in research and treatment. Using tumor tissues provided by the Children’s Brain Tumor Network, researchers hope to identify new avenues for treatment.

Project

Asset 23.png

Specimen

Planning

CDC42 RHOJ Interaction Inhibitors for the Treatment of Neurofibromatosis

Neurofibromatosis type 2 (NF2) tumors can cause significant hearing loss and current therapies can accelerate this loss through the impact of side effects and non compliance. Using cell lines provided by the Children’s Brain Tumor Network, researchers are testing new treatments to address this issue.

Anand Ganesan

Anand Ganesan

University of California, Irvine
Irvine, CA, USA